Preventing neutropenia from sacituzumab govitecan in TNBC
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether a drug called sacituzumab govitecan can help prevent a low white blood cell count (neutropenia) in people with metastatic triple-negative breast cancer. It is for patients who have already received some chemotherapy but need a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- Your cancer is triple-negative breast cancer that has spread to other parts of the body (metastatic).
- You have already tried at least one but no more than two standard chemotherapy treatments for this advanced cancer.
- You have been treated with a taxane chemotherapy (like paclitaxel or docetaxel) in the past.
- You have not had a type of chemotherapy called a topoisomerase 1 inhibitor, such as irinotecan or topotecan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called sacituzumab govitecan (a type of antibody-drug conjugate that targets cancer cells) as the first treatment for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if it can help shrink or control the cancer.
This study looks at how well the drug Sacituzumab Govitecan works in real-life settings for people with certain types of advanced breast cancer that have not responded to prior treatments.
This study looks at how well a drug called sacituzumab govitecan works and how safe it is for people with a certain type of breast cancer that has spread (HER2-negative metastatic breast cancer). It aims to understand real-world results for patients in China.
This trial is studying how patients with metastatic triple-negative breast cancer feel and function during treatment with sacituzumab govitecan (a targeted therapy) or standard chemotherapy, using patient-reported outcomes. It aims to better understand the real-world effectiveness and impact on quality of life in Chinese patients.
This trial tests a drug called sacituzumab govitecan for people with newly diagnosed triple-negative breast cancer (TNBC) that hasn't been treated yet. The drug targets cancer cells directly to try to stop them from growing.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
Hear when a new Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.